相关实验视频

Updated: Jun 28, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

通过影响M1巨细胞透的TP53相关基因确定SLC2A6为乳腺癌的新型保护因子

Chao Dai¹, Yuxin Man², Luhan Zhang¹

¹Sichuan Provincial Key Laboratory for Human Disease Gene Study and Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.

Apoptosis : an international journal on programmed cell death

|April 15, 2024

概括

这项研究确定了影响M1巨细胞透的TP53突变相关的乳腺癌 (BC) 亚型. 一个新的风险特征突出显示SLC2A6是BC的潜在瘤抑制剂和免疫治疗生物标志物.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

由于基因突变而导致的乳腺癌 (BC) 异质性使免疫疗法的有效性复杂化.
TP53突变会影响M1巨细胞的透,这是BC免疫治疗反应的关键因素.
了解这些机制对于开发新的BC治疗策略至关重要.

研究的目的:

根据与TP53相关的M1巨菌透,开发一种BC分子类型的风险特征.
识别和评估关键基因作为潜在的免疫疗法生物标记物的功能作用.
阐明在BC进展中识别的基因的潜在机制.

主要方法:

权重基因共同表达网络分析 (WGCNA) 和非负矩阵因子分解 (NMF) 用于BC亚型识别.
构建和验证风险签名和名录图用于预后预测.
在体外和体内实验,以确认标志性基因SLC2A6.6的生物功能.
用RNA测序和蛋白质基因分析来研究分子机制.

主要成果:

确定了四种不同的BC亚型,与TP53相关的基因和M1巨细胞透有关.
开发的风险特征有效评估了BC临床特征和瘤微环境.
诺米图表在预测患者预后方面表现出很高的准确性.
新型特征基因SLC2A6在瘤组织中表达低;其过度表达抑制了增殖,诱导了线粒体损伤,并促进了亡.
鉴定出HSPA6是SLC2A6的结合蛋白,表达水平正相关.

结论:

确定的风险标志是BC风险评估和理解瘤异质性的宝贵工具.
基因SLC2A6在乳腺癌中起到瘤抑制作用,是免疫疗法的有希望的生物标志物.
准SLC2A6或相关途径可能为乳腺癌治疗提供新的治疗途径.

关键词:

乳腺癌乳腺癌是什么?巨细胞是一个巨细胞.线粒体损伤导致线粒体损伤.在SLC2A6A6中.这就是TP53的特点.瘤微环境是一个微环境.

更多相关视频

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...